Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team
June 03, 2021 16:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...
Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer
June 01, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences to Present at Upcoming Investor Conferences in June
May 26, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting
May 13, 2021 07:00 ET
|
Evelo Biosciences, Inc.
–On-track to initiate clinical development of EDP2939 in 2022– CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company...
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
April 29, 2021 07:00 ET
|
Evelo Biosciences, Inc.
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief...
Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
April 22, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
April 20, 2021 16:01 ET
|
Evelo Biosciences, Inc.
–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting– –Meaningful improvements over placebo on clinical scores, including new data released on key...
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
April 15, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
April 05, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
March 23, 2021 03:00 ET
|
Evelo Biosciences, Inc.
-- Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in...